Kenya's PrEP collapse exposes the cost of donor dependence

At a public HIV clinic along Moi Avenue in Nairobi, the PrEP refill line that once stretched past the parking gate is now three deep and shrinking. Pharmacists who spent the late 2010s dispensing pre-exposure prophylaxis by the thousand have watched monthly prescriptions slide to a fraction of their peak. The collapse is not a slow drift; according to Daily Nation reporting on 15 July 2026, Kenya's PrEP uptake has fallen by roughly 80% as donor funding has dried up. The number is the sort of figure that normally arrives with a footnote. This one arrives with a generation of risk attached to it.

What is unfolding in Kenya is a stress test for an idea that governed much of African public-health policy in the previous decade: that the global HIV response could be financed largely from outside the continent, and that prevention commodities could be delivered through Western donor architecture with minimal domestic budgetary exposure. That arrangement delivered measurable results. It also made Kenya's prevention footprint structurally fragile, in ways the country is now being forced to price in real time.

The 80% number

The figure reported by Daily Nation is not a forecast; it is a recorded drop in uptake across a national PrEP programme that, at its 2022–2023 high point, was enrolling new users at a pace that placed Kenya among the more successful rollout markets in eastern Africa. The cutback tracks a familiar sequence. The United States government's flagship HIV donor account, the President's Emergency Plan for AIDS Relief, has been the principal external financier of Kenya's PrEP procurement and last-mile distribution. As that pipeline contracts, the supply side contracts first: clinics run out of the tenofovir-based regimens used for daily oral PrEP, outreach workers funded through donor implementing partners are redeployed or let go, and the routine HIV testing that serves as the entry point for new PrEP enrolments thins out.

Demand does not evaporate on the same timetable. It leaks. Existing users skip refills. Eligible adolescents and sex workers, the two cohorts where PrEP has done the most documented work in Kenya, lose touch with the clinic. New infections that would have been averted become harder to attribute later, because by the time they show up in surveillance data, the prevention programme they would have been counted against is no longer functioning at scale.

Why this matters beyond the clinic

HIV prevention is not a single commodity. It is a stack: testing infrastructure, counselling staff, dispensing pharmacists, lab capacity to monitor renal function in long-term PrEP users, peer educators in the informal settlements of Kibera and Mathare, sex-worker-friendly drop-in centres in Mombasa and Kisumu. The donor funding that built that stack was, in the framing of its architects, an emergency response. Two decades on, the emergency framing has not aged well. A country of more than 50 million people, with adult HIV prevalence still in the high single digits for key populations, has been running a flagship prevention intervention on an emergency budget.

The structural problem is not new, and it is not uniquely Kenyan. Donor-financed health systems across sub-Saharan Africa are confronting the same arithmetic: external HIV funding has been flat-to-declining for several budget cycles, domestic resource mobilisation has not closed the gap, and the commodities that donors once covered almost entirely are now partially exposed to national treasuries that have their own debt-service and wage bill to manage. Kenya is among the better-positioned economies on the continent to absorb the shock. That it is registering an 80% collapse in uptake is the more telling data point.

The countervailing argument

The donors' case for the arrangement that is now unwinding is not hollow. PEPFAR and the Global Fund delivered PrEP to populations that domestic health budgets, in the era before Kenya's 2010 devolution, would not have reached at any comparable scale. The cost per infection averted, by the standard health-economics metrics, was competitive with public-health spending anywhere. And the dollar amounts, in absolute terms, were modest by the standards of the donor countries that wrote the cheques. The critique that African health systems became over-reliant on external funding is, in this reading, the same critique that could be levelled at any recipient of concentrated external support, from post-war European reconstruction to the Marshall Plan.

What changes the calculation is duration. An emergency that lasts two decades stops being an emergency and starts being a budget line. A budget line that no one inside the recipient government owns, because no constituency votes on it and no ministry administers it directly, is a budget line that disappears when the donor's political mood shifts.

What is actually being lost

The clinics are not closing. Kenya's HIV treatment programme, the antiretroviral therapy backbone that keeps more than a million people virally suppressed, remains in place through a mix of donor and domestic financing. What is contracting is the prevention margin: the daily pill taken by an HIV-negative sex worker in Kawangware, the three-monthly injectable cabotegravir that was beginning to reach adolescent girls in Migori, the counselling session that walks a young man through his risk profile. Each of those encounters is cheap at the margin, in the way that all prevention is cheap once it exists and expensive once it has to be rebuilt.

There is also an epistemic cost. The data systems that record PrEP uptake, adherence, and seroconversion were, in large part, built and maintained through the same donor projects now drawing down. When the programmes contract, the data contracts with them. Kenya's ability to track its own HIV epidemic in the cohorts where PrEP was making a difference will degrade in parallel with the programmes themselves.

The structural frame

This is the pattern that recurs wherever a national public-health strategy is built principally on someone else's balance sheet. The strategy succeeds, the donor declares victory, the funding is redeployed to a newer emergency, and the recipient state is left running a system it did not budget for and cannot, in the short run, fully replace. The pharmaceutical logistics, the community-health-worker payrolls, the supply-chain contracts that get PrEP from a manufacturer's plant in India to a dispensary in Homa Bay: these were stitched together by external money, often on external timelines, and the seams show when the money goes.

The honest reframe is that this is not a Kenyan failure. It is the predictable late-cycle cost of a financing model that has, until now, produced results good enough to defer the question of who owns the prevention budget once the donors move on.

What to watch

The Daily Nation reporting points to the immediate pressure points: clinic-level stockouts, the wind-down of donor-funded community outreach, and the absence of a clearly costed domestic replacement plan. The next data points worth tracking are the quarterly PrEP initiation numbers that Kenya's Ministry of Health publishes through the National AIDS and STI Control Programme, the cabinet-level decisions on whether and how to fold PrEP procurement into the national medical supplies authority budget, and any re-engagement from PEPFAR or the Global Fund as their own fiscal years reset.

What remains uncertain is the denominator. The 80% figure is a national headline; the subnational breakdown, particularly between high-burden counties in the lake region and lower-burden urban centres, will determine whether the next infection data tells a story of generalised backsliding or a sharper, more localised one. The sources published on 15 July 2026 do not yet give that detail.

This article draws on Daily Nation's health-desk reporting dated 15 July 2026. Monexus has read the figures against the standard public-health economics of donor-financed HIV programmes and treated the 80% drop as a recorded statistic, not a projection. The framing question, of how much prevention infrastructure a middle-income African state should expect to fund from its own books, is one the wire services have largely left to the health ministries; this publication does not.